
Argenx receives positive CHMP opinion for CIDP treatment
VYVGART could be the first CIDP drug with a novel mechanism in 30 years Argenx has announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended European Commission (EC) approval for VYVGART (efgartigimod alfa) as a subcutaneous …